Clean air for Pharmaxis
Wednesday, 13 August, 2008
Results from the Phase II clinical trial of Pharmaxis' [ASX: PXS] Bronchitol treatment in cystic fibrosis patients have produced promising results.
The study showed that Bronchitol was able to improve lung function in cystic fibrosis sufferers, as measured by forced vital capacity and FEV1 - the amount of air that can be forcibly exhaled in one second.
Improvements in lung function were dose-dependant, with the best results occurring in the patients which had received the highest dose. Pharmaxis has concluded that 400mg is the optimal Bronchitol dose.
Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. It is a proprietary formulation of mannitol, administered as a dry powder through a hand-held inhaler.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
